Gara Samara Brajadenta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gara Samara Brajadenta has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Vincent Thoreau
Medicine and Pharmacy Faculty, University of Poitiers, Poitiers, France
3 shared publications A Kitzis
EA3808 Neurovascular Unit and Cognitive Impairments, University of Poitiers, Poitiers, France
1 shared publicationAgung Saprasetya Dwi Laksana
Faculty of Medicine, Jenderal Soedirman University, Purwokerto
1 shared publication- Agustini Utari
Center for Biomedical Research (CEBIOR), Faculty of Medicine, Diponegoro University, Semarang, Indonesia
1 shared publication Alain Kitzis
Neurovascular Unit and Cognitive Disorders (EA-3808 NEUVACOD), Université de Poitiers, Poitiers, France
1 shared publication- Alain Kitzis
EA3808 Neurovascular Unit and Cognitive Impairments, University of Poitiers, Poitiers, France
1 shared publication
Latest Publications
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Development of a functional assay for CHD7, a protein involved in CHARGE syndrome
Mise au point d'un test fonctionnel pour la protéine CHD7 impliquée dans le syndrome CHARGE: Le syndrome CHARGE (CS) est une maladie génétique rare caractérisée par de nombreuses anomalies congénitales, majoritairement causées par des altérations de novo du gène CHD7. Celui-ci code pour une protéine à chromodomaines, impliquée dans le remodelage ATP-dépendant de la chromatine. La grande majorité des altérations de CHD7 consiste en allèles nuls tels que des délétions, des substitutions non-sens ou des décalages du cadre de lecture. Nous avons réalisé le premier diagnostic moléculaire d’un patient Indonésien atteint du CS, en étudiant un panel de gènes (CHD7, EFTUD2, et HOXA1) par NGS (next-generation sequencing). Nous avons identifié une nouvelle mutation non-sens hétérozygote dans l’exon 34 du gène CHD7 (c.7234G>T ou p.Glu2412Ter). Par ailleurs, il n'existe pas d’analyse fonctionnelle qui permettrait de caractériser la pathogénicité des variants de la protéine CHD7 rencontrés chez des patients. C’est pourquoi l’objectif de ce travail est de mettre au point un test fonctionnel de la protéine CHD7, sous forme sauvage ou mutée. Pour cela, nous avons généré par mutagénèse dirigée des vecteurs codant pour trois variants faux-sens de CHD7 et le variant présentant une insertion de cinq acides aminés. Ensuite, les protéines CHD7, sous forme sauvage ou variante, ont été surexprimées dans la lignée HeLa. L’expression des protéines a été mise en évidence par western blot et par immunofluorescence. Pour étudier la fonctionnalité de CHD7, nous avons quantifié par RT-qPCR les transcrits de cinq gènes (l’ADNr 45S, SOX4, SOX10, MYRF, et ID2), dont la transcription est selon le littérature régulée par CHD7. Nous avons observé que l’expression de CHD7 sauvage entraînait une diminution significative et reproductible des quantités de transcrits correspondant à tous les gènes rapporteurs. Par contre, l’expression des quatre allèles variants de CHD7 n’avait aucun impact, ce qui suggère que ces variants ne sont pas fonctionnels. Par ailleurs, nous avons appliqué notre test biologique dans des cellules de la lignée SH-SY5Y, pour lesquelles nous avons introduit une mutation faux-sens dans le génome en utilisant la technique CRISPR/Cas9. Lorsque ce variant était exprimé, les niveaux de transcription des cinq gènes rapporteurs n’étaient pas significativement différents de ceux observés dans les cellules où les deux allèles de CHD7 avaient été invalidés. Par conséquent, les variants étudiés peuvent être répertoriés comme résultant de mutations causales du CS.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Development of a functional assay for CHD7, a protein involved in CHARGE syndrome
Mise au point d'un test fonctionnel pour la protéine CHD7 impliquée dans le syndrome CHARGE: Le syndrome CHARGE (CS) est une maladie génétique rare caractérisée par de nombreuses anomalies congénitales, majoritairement causées par des altérations de novo du gène CHD7. Celui-ci code pour une protéine à chromodomaines, impliquée dans le remodelage ATP-dépendant de la chromatine. La grande majorité des altérations de CHD7 consiste en allèles nuls tels que des délétions, des substitutions non-sens ou des décalages du cadre de lecture. Nous avons réalisé le premier diagnostic moléculaire d’un patient Indonésien atteint du CS, en étudiant un panel de gènes (CHD7, EFTUD2, et HOXA1) par NGS (next-generation sequencing). Nous avons identifié une nouvelle mutation non-sens hétérozygote dans l’exon 34 du gène CHD7 (c.7234G>T ou p.Glu2412Ter). Par ailleurs, il n'existe pas d’analyse fonctionnelle qui permettrait de caractériser la pathogénicité des variants de la protéine CHD7 rencontrés chez des patients. C’est pourquoi l’objectif de ce travail est de mettre au point un test fonctionnel de la protéine CHD7, sous forme sauvage ou mutée. Pour cela, nous avons généré par mutagénèse dirigée des vecteurs codant pour trois variants faux-sens de CHD7 et le variant présentant une insertion de cinq acides aminés. Ensuite, les protéines CHD7, sous forme sauvage ou variante, ont été surexprimées dans la lignée HeLa. L’expression des protéines a été mise en évidence par western blot et par immunofluorescence. Pour étudier la fonctionnalité de CHD7, nous avons quantifié par RT-qPCR les transcrits de cinq gènes (l’ADNr 45S, SOX4, SOX10, MYRF, et ID2), dont la transcription est selon le littérature régulée par CHD7. Nous avons observé que l’expression de CHD7 sauvage entraînait une diminution significative et reproductible des quantités de transcrits correspondant à tous les gènes rapporteurs. Par contre, l’expression des quatre allèles variants de CHD7 n’avait aucun impact, ce qui suggère que ces variants ne sont pas fonctionnels. Par ailleurs, nous avons appliqué notre test biologique dans des cellules de la lignée SH-SY5Y, pour lesquelles nous avons introduit une mutation faux-sens dans le génome en utilisant la technique CRISPR/Cas9. Lorsque ce variant était exprimé, les niveaux de transcription des cinq gènes rapporteurs n’étaient pas significativement différents de ceux observés dans les cellules où les deux allèles de CHD7 avaient été invalidés. Par conséquent, les variants étudiés peuvent être répertoriés comme résultant de mutations causales du CS.
- Open Access
- 1 October 2019
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1360 (1) , 012002
Localization study of CHD7 protein expressed in HeLa and HEK293 cells
CHARGE syndrome is a rare genetic disease characterized by numerous congenital abnormalities caused by de novo alterations of the CHD7 gene. It encodes a chromo domain protein, involved in the ATP-dependent remodelling of chromatin. It has been described that CHD7 protein plays a role as a positive regulator of the nucleolar expression of the 45S ribosomal RNA precursor. The aim of this research was to study where the CHD7 protein is localized. Knowledge of the subcellular localization of the CHD7 protein is essential for understanding its physiological function. This study was conducted by transfection of two plasmids encoding CHD7-HA or FLAG-CHD7 into HeLa (human cervix carcinoma) and HEK293 (human embryonic kidney) cells. Protein expression and localization of the CHD7 protein was demonstrated by western blot and immunofluorescence. CHD7 protein was expressed in both cell models, and localization of the protein was found in the nucleoplasm, but not in the nucleolus.
- 1 October 2019
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1360 (1) , 012002
Open AccessLocalization study of CHD7 protein expressed in HeLa and HEK293 cells
CHARGE syndrome is a rare genetic disease characterized by numerous congenital abnormalities caused by de novo alterations of the CHD7 gene. It encodes a chromo domain protein, involved in the ATP-dependent remodelling of chromatin. It has been described that CHD7 protein plays a role as a positive regulator of the nucleolar expression of the 45S ribosomal RNA precursor. The aim of this research was to study where the CHD7 protein is localized. Knowledge of the subcellular localization of the CHD7 protein is essential for understanding its physiological function. This study was conducted by transfection of two plasmids encoding CHD7-HA or FLAG-CHD7 into HeLa (human cervix carcinoma) and HEK293 (human embryonic kidney) cells. Protein expression and localization of the CHD7 protein was demonstrated by western blot and immunofluorescence. CHD7 protein was expressed in both cell models, and localization of the protein was found in the nucleoplasm, but not in the nucleolus.
- Open Access
- 1 September 2019
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 39 (5) , 503-506
Identification of a Novel CHD7 Mutation in a CHARGE Syndrome Patient in Indonesia
Brajadenta GS, et al. Ann Lab Med. 2019 Sep;39(5):503-506. https://doi.org/10.3343/alm.2019.39.5.503
- 1 September 2019
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 39 (5) , 503-506
Open AccessIdentification of a Novel CHD7 Mutation in a CHARGE Syndrome Patient in Indonesia
Brajadenta GS, et al. Ann Lab Med. 2019 Sep;39(5):503-506. https://doi.org/10.3343/alm.2019.39.5.503
- Open Access
- 7 August 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-6
Molecular analysis of exon 7 of the fibroblast growth factor receptor 2 (FGFR2) gene in an Indonesian patient with Apert syndrome: a case report
Apert syndrome, Online Mendelian Inheritance in Man number 101200, is a rare genetic condition, with autosomal dominant inheritance, characterized by craniosynostosis, midfacial malformation, and severe symmetrical syndactyly. Apert syndrome is associated with other systemic malformations, including intellectual disability. At least seven mutations in fibroblast growth factor receptor 2 (FGFR2) gene have been found to cause Apert syndrome. Most cases of Apert syndrome are caused by one of the two most frequent mutations located in exon 7 (Ser252Trp or Pro253Arg). A 27-year-old Javanese man presented borderline intellectual functioning and striking dysmorphisms. A clinical diagnosis of Apert syndrome was previously made based on these clinical features. Furthermore, POSSUM software was used before molecular analysis and the result showed suspected Apert syndrome with a cut-off point of 14. Molecular genetic analysis of FGFR2, targeting exon 7, was performed by direct sequencing. In this patient, a missense mutation c.755C>G was detected, changing a serine into a tryptophan (p.Ser252Trp). We report the case of an Indonesian man with Apert syndrome with a c.755C>G (p.Ser252Trp) mutation in the FGFR2 gene. Our patient showed similar dysmorphism to previously reported cases, although cleft palate as a typical feature for p.Ser252Trp mutation was not present. In spite of the accessibility of molecular genetic testing in a few parts of the world, the acknowledgement of clinically well-defined syndromes will remain exceptionally imperative in developing countries with a lack of diagnostic facilities.
- 7 August 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-6
Open AccessMolecular analysis of exon 7 of the fibroblast growth factor receptor 2 (FGFR2) gene in an Indonesian patient with Apert syndrome: a case report
Apert syndrome, Online Mendelian Inheritance in Man number 101200, is a rare genetic condition, with autosomal dominant inheritance, characterized by craniosynostosis, midfacial malformation, and severe symmetrical syndactyly. Apert syndrome is associated with other systemic malformations, including intellectual disability. At least seven mutations in fibroblast growth factor receptor 2 (FGFR2) gene have been found to cause Apert syndrome. Most cases of Apert syndrome are caused by one of the two most frequent mutations located in exon 7 (Ser252Trp or Pro253Arg). A 27-year-old Javanese man presented borderline intellectual functioning and striking dysmorphisms. A clinical diagnosis of Apert syndrome was previously made based on these clinical features. Furthermore, POSSUM software was used before molecular analysis and the result showed suspected Apert syndrome with a cut-off point of 14. Molecular genetic analysis of FGFR2, targeting exon 7, was performed by direct sequencing. In this patient, a missense mutation c.755C>G was detected, changing a serine into a tryptophan (p.Ser252Trp). We report the case of an Indonesian man with Apert syndrome with a c.755C>G (p.Ser252Trp) mutation in the FGFR2 gene. Our patient showed similar dysmorphism to previously reported cases, although cleft palate as a typical feature for p.Ser252Trp mutation was not present. In spite of the accessibility of molecular genetic testing in a few parts of the world, the acknowledgement of clinically well-defined syndromes will remain exceptionally imperative in developing countries with a lack of diagnostic facilities.
- 9 July 2019
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 27 (11) , 1683-1691
A functional assay to study the pathogenicity of CHD7 protein variants encountered in CHARGE syndrome patients
CHARGE syndrome is a rare genetic disease characterized by numerous congenital abnormalities, mainly caused by de novo alterations of the CHD7 gene. It encodes a chromodomain protein, involved in the ATP-dependent remodeling of chromatin. The vast majority of CHD7 alterations consists in null alleles like deletions, nonsense substitutions or frameshift-causing variations. The aim of this study was to develop a biological test of CHD7 protein, to study the impact upon protein functionality of rare allelic variants in the CHD7 gene that elicits changes in the amino acid sequence. Using an expression vector encoding CHD7, three amino acid substitutions and one five-amino acid insertion were generated via site-directed mutagenesis. Then CHD7 proteins, either wild-type (WT) or variants, were overexpressed in HeLa cell line. Protein expression was highlighted by western blot and immunofluorescence. We then used real-time RT-PCR to study CHD7 functionality by evaluating the transcript amounts of five genes whose expression is regulated by CHD7 according to the literature. These reporter genes are 45S rDNA, SOX4, SOX10, ID2, and MYRF. We observed that, upon WT-CHD7 expression, the reporter gene transcriptions were downregulated, whereas the four variant alleles of CHD7 had no impact. This suggests that these alleles are not polymorphisms because the variant proteins appeared nonfunctional. Therefore, these variations can be considered as disease-causing of CHARGE syndrome.
- 9 July 2019
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 27 (11) , 1683-1691
A functional assay to study the pathogenicity of CHD7 protein variants encountered in CHARGE syndrome patients
CHARGE syndrome is a rare genetic disease characterized by numerous congenital abnormalities, mainly caused by de novo alterations of the CHD7 gene. It encodes a chromodomain protein, involved in the ATP-dependent remodeling of chromatin. The vast majority of CHD7 alterations consists in null alleles like deletions, nonsense substitutions or frameshift-causing variations. The aim of this study was to develop a biological test of CHD7 protein, to study the impact upon protein functionality of rare allelic variants in the CHD7 gene that elicits changes in the amino acid sequence. Using an expression vector encoding CHD7, three amino acid substitutions and one five-amino acid insertion were generated via site-directed mutagenesis. Then CHD7 proteins, either wild-type (WT) or variants, were overexpressed in HeLa cell line. Protein expression was highlighted by western blot and immunofluorescence. We then used real-time RT-PCR to study CHD7 functionality by evaluating the transcript amounts of five genes whose expression is regulated by CHD7 according to the literature. These reporter genes are 45S rDNA, SOX4, SOX10, ID2, and MYRF. We observed that, upon WT-CHD7 expression, the reporter gene transcriptions were downregulated, whereas the four variant alleles of CHD7 had no impact. This suggests that these alleles are not polymorphisms because the variant proteins appeared nonfunctional. Therefore, these variations can be considered as disease-causing of CHARGE syndrome.
- Open Access
- 3 February 2019
- Published by Sekolah Tinggi Ilmu Kesehatan Kapuas Raya Sintang in Jurnal Ilmiah Ilmu Kesehatan: Wawasan Kesehatan
- Vol. 5 (2)
EFEK TERAPI OBAT ANTI TUBERKULOSIS TERHADAP LAJU ENDAP DARAH: STUDI PADA PASIEN TUBERKULOSIS ANAK
Laju endap darah (LED) merupakan salah satu elemen pemeriksaan darah rutin. Pemeriksaan laboratorium penunjang tersebut juga dapat digunakan untuk mengetahui respon dalam suatu pengobatan tuberkulosis (TB). Namun demikian, hubungan antara terapi obat anti tuberkulosis (OAT) dengan LED belum banyak dijelaskan di dalam literatur. Penelitian ini bertujuan untuk menganalisis efek terapi OAT lini pertama terhadap LED pada pasien TB anak. Penelitian ini merupakan penelitian observasional analitik. Populasi adalah pasien TB anak di instalasi rawat jalan RSUD. Prof. Dr. Margono Soekarjo yang mendapatkan terapi OAT lini pertama. Penarikan sampel menggunakan total sampling, semua pasien TB anak yang diberikan terapi 9 bulan OAT lini pertama selama penelitian berlangsung. Digunakan uji t berpasangan untuk menguji signifikasi perbedaan angka LED sebelum dan sesudah terapi OAT. Hasil analisis uji t signifikan sig.=0,000 (0,000<0,05), terapi OAT lini pertama selama 9 bulan pada pasien TB anak terbukti dapat menurunkan angka LED.
- 3 February 2019
- Published by Sekolah Tinggi Ilmu Kesehatan Kapuas Raya Sintang in Jurnal Ilmiah Ilmu Kesehatan: Wawasan Kesehatan
- Vol. 5 (2)
Open AccessEFEK TERAPI OBAT ANTI TUBERKULOSIS TERHADAP LAJU ENDAP DARAH: STUDI PADA PASIEN TUBERKULOSIS ANAK
Laju endap darah (LED) merupakan salah satu elemen pemeriksaan darah rutin. Pemeriksaan laboratorium penunjang tersebut juga dapat digunakan untuk mengetahui respon dalam suatu pengobatan tuberkulosis (TB). Namun demikian, hubungan antara terapi obat anti tuberkulosis (OAT) dengan LED belum banyak dijelaskan di dalam literatur. Penelitian ini bertujuan untuk menganalisis efek terapi OAT lini pertama terhadap LED pada pasien TB anak. Penelitian ini merupakan penelitian observasional analitik. Populasi adalah pasien TB anak di instalasi rawat jalan RSUD. Prof. Dr. Margono Soekarjo yang mendapatkan terapi OAT lini pertama. Penarikan sampel menggunakan total sampling, semua pasien TB anak yang diberikan terapi 9 bulan OAT lini pertama selama penelitian berlangsung. Digunakan uji t berpasangan untuk menguji signifikasi perbedaan angka LED sebelum dan sesudah terapi OAT. Hasil analisis uji t signifikan sig.=0,000 (0,000<0,05), terapi OAT lini pertama selama 9 bulan pada pasien TB anak terbukti dapat menurunkan angka LED.
- 5 November 2018
- Published by Universitas Strada Indonesia in STRADA : Jurnal Ilmiah Kesehatan
- Vol. 7 (2) , 1-6
Faktor Risiko Tuberkulosis Paru Anak: Studi pada Balai Kesehatan Paru Masyarakat (BKPM) Purwokerto
Tuberkulosis (TB) paru masih merupakan masalah kesehatan di seluruh dunia, oleh karena morbiditas dan mortalitasnya masih tinggi, terutama pada negara yang sedang berkembang. Jumlah anak Indonesia usia di bawah 15 tahun adalah 40-50% dari jumlah seluruh populasi. Infeksi TB pada anak merupakan cikal bakal (reservoir) untuk berkembangnya penyakit TB pada dewasa. Tujuan penelitian untuk menganalisis pengaruh faktor risiko terkait status gizi, status imunisasi BCG, usia anak, pengetahuan orang tua tentang TB, kontak dekat dengan penderita TB terhadap terjadinya penyakit tuberkulosis anak. Penelitian ini menggunakan desain cross-sectional. Populasi penelitian pasien anak usia 0-14 tahun yang berobat di Balai Kesehatan Paru Masyarakat (BKPM) Purwokerto. Sampel sebanyak 240 pasien. Analisis data menggunakan chi-square dan multiple regresi logistic. Faktor risiko usia anak, pengetahuan orangtua tentang TB, serta kontak dekat dengan penderita TB dewasa berpengaruh signifikan terhadap kejadian penyakit TB pada anak. Kontak dekat dengan penderita TB merupakan faktor yang paling berpengaruh dibandingkan faktor lainnya.
- 5 November 2018
- Published by Universitas Strada Indonesia in STRADA : Jurnal Ilmiah Kesehatan
- Vol. 7 (2) , 1-6
Faktor Risiko Tuberkulosis Paru Anak: Studi pada Balai Kesehatan Paru Masyarakat (BKPM) Purwokerto
Tuberkulosis (TB) paru masih merupakan masalah kesehatan di seluruh dunia, oleh karena morbiditas dan mortalitasnya masih tinggi, terutama pada negara yang sedang berkembang. Jumlah anak Indonesia usia di bawah 15 tahun adalah 40-50% dari jumlah seluruh populasi. Infeksi TB pada anak merupakan cikal bakal (reservoir) untuk berkembangnya penyakit TB pada dewasa. Tujuan penelitian untuk menganalisis pengaruh faktor risiko terkait status gizi, status imunisasi BCG, usia anak, pengetahuan orang tua tentang TB, kontak dekat dengan penderita TB terhadap terjadinya penyakit tuberkulosis anak. Penelitian ini menggunakan desain cross-sectional. Populasi penelitian pasien anak usia 0-14 tahun yang berobat di Balai Kesehatan Paru Masyarakat (BKPM) Purwokerto. Sampel sebanyak 240 pasien. Analisis data menggunakan chi-square dan multiple regresi logistic. Faktor risiko usia anak, pengetahuan orangtua tentang TB, serta kontak dekat dengan penderita TB dewasa berpengaruh signifikan terhadap kejadian penyakit TB pada anak. Kontak dekat dengan penderita TB merupakan faktor yang paling berpengaruh dibandingkan faktor lainnya.